Use of non-toxic antimicrobial, oxychlorine, hypochlorous acid and superoxidized water products Download PDF

Info

Publication number WO2010025305A1 PCT/US2009/055258 US2009055258W WO2010025305A1 WO 2010025305 A1 WO2010025305 A1 WO 2010025305A1 US 2009055258 W US2009055258 W US 2009055258W WO 2010025305 A1 WO2010025305 A1 WO 2010025305A1 Authority Prior art keywords pathogenic microorganism Prior art date

Application number

Other languages

Inventor

Original Assignee

Drug Enhancement Company Of America, Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

Filing date

Publication date

Priority claimed from US9236308P external-priority

2009-08-27 Application filed by Drug Enhancement Company Of America, Llc filed Critical Drug Enhancement Company Of America, Llc

2010-03-04 Publication of WO2010025305A1 publication Critical patent/WO2010025305A1/en

Links

• QWPPOHNGKGFGJK-UHFFFAOYSA-N Hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 title claims description 31
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 22
• 230000003000 nontoxic Effects 0.000 title claims description 9
• 231100000252 nontoxic Toxicity 0.000 title claims description 9
• 230000000845 anti-microbial Effects 0.000 title description 9
• 244000052616 bacterial pathogens Species 0.000 claims abstract description 71
• 239000000203 mixture Substances 0.000 claims abstract description 28
• 239000003795 chemical substances by application Substances 0.000 claims description 152
• 230000000694 effects Effects 0.000 claims description 51
• 201000010099 disease Diseases 0.000 claims description 41
• 241000700605 Viruses Species 0.000 claims description 36
• 241000894006 Bacteria Species 0.000 claims description 33
• 241000124008 Mammalia Species 0.000 claims description 25
• FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 25
• 201000009910 diseases by infectious agent Diseases 0.000 claims description 21
• 201000001042 variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 20
• 208000003055 Prion Disease Diseases 0.000 claims description 15
• 241000315672 SARS coronavirus Species 0.000 claims description 15
• 239000011780 sodium chloride Substances 0.000 claims description 14
• SUKJFIGYRHOWBL-UHFFFAOYSA-N Sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 13
• 150000001875 compounds Chemical class 0.000 claims description 13
• 239000005708 Sodium hypochlorite Substances 0.000 claims description 11
• 208000005881 Bovine Spongiform Encephalopathy Diseases 0.000 claims description 10
• 201000007406 chronic wasting disease Diseases 0.000 claims description 10
• 241000711573 Coronaviridae Species 0.000 claims description 9
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 9
• 201000010450 Creutzfeldt-Jakob disease Diseases 0.000 claims description 9
• 241000233866 Fungi Species 0.000 claims description 9
• 230000001580 bacterial Effects 0.000 claims description 9
• 230000005540 biological transmission Effects 0.000 claims description 9
• 201000003176 severe acute respiratory syndrome Diseases 0.000 claims description 9
• 241000203069 Archaea Species 0.000 claims description 8
• 241000193738 Bacillus anthracis Species 0.000 claims description 8
• 241000223205 Coccidioides immitis Species 0.000 claims description 8
• 241001115402 Ebolavirus Species 0.000 claims description 8
• 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 8
• 241000607479 Yersinia pestis Species 0.000 claims description 8
• 239000000443 aerosol Substances 0.000 claims description 8
• 210000004666 bacterial spores Anatomy 0.000 claims description 8
• 230000003612 virological Effects 0.000 claims description 8
• 241000193155 Clostridium botulinum Species 0.000 claims description 7
• 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 claims description 7
• 241000725303 Human immunodeficiency virus Species 0.000 claims description 7
• 241000712902 Lassa mammarenavirus Species 0.000 claims description 7
• 241001115401 Marburgvirus Species 0.000 claims description 7
• 241000526636 Nipah henipavirus Species 0.000 claims description 7
• 241000150452 Orthohantavirus Species 0.000 claims description 7
• 208000001203 Smallpox Diseases 0.000 claims description 7
• 229940076185 Staphylococcus aureus Drugs 0.000 claims description 7
• 241000191967 Staphylococcus aureus Species 0.000 claims description 7
• 201000009906 meningitis Diseases 0.000 claims description 7
• 201000006266 variola major Diseases 0.000 claims description 7
• 229940065181 Bacillus anthracis Drugs 0.000 claims description 6
• 206010006326 Breath odour Diseases 0.000 claims description 6
• 206010012735 Diarrhoea Diseases 0.000 claims description 6
• 229940118764 FRANCISELLA TULARENSIS Drugs 0.000 claims description 6
• 241000589602 Francisella tularensis Species 0.000 claims description 6
• 241000606768 Haemophilus influenzae Species 0.000 claims description 6
• 241000588653 Neisseria Species 0.000 claims description 6
• 241000712910 Pichinde mammarenavirus Species 0.000 claims description 6
• 206010047700 Vomiting Diseases 0.000 claims description 6
• 229940118695 Yersinia pestis Drugs 0.000 claims description 6
• 201000008286 diarrhea Diseases 0.000 claims description 6
• 230000000699 topical Effects 0.000 claims description 6
• 208000008581 Brain Disease Diseases 0.000 claims description 5
• 206010014623 Encephalopathy Diseases 0.000 claims description 5
• 206010014625 Encephalopathy Diseases 0.000 claims description 5
• 241000282324 Felis Species 0.000 claims description 5
• 206010072075 Gerstmann Straussler Scheinker syndrome Diseases 0.000 claims description 5
• 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 claims description 5
• 229940047650 Haemophilus influenzae Drugs 0.000 claims description 5
• 241000712890 Junin mammarenavirus Species 0.000 claims description 5
• 241000772415 Neovison vison Species 0.000 claims description 5
• 102000033170 PRNP Human genes 0.000 claims description 5
• 101710024107 PRNP Proteins 0.000 claims description 5
• 229940055023 Pseudomonas aeruginosa Drugs 0.000 claims description 5
• 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
• 208000008864 Scrapie Diseases 0.000 claims description 5
• 229940031000 Streptococcus pneumoniae Drugs 0.000 claims description 5
• 241000193998 Streptococcus pneumoniae Species 0.000 claims description 5
• 201000006061 fatal familial insomnia Diseases 0.000 claims description 5
• 208000005577 Gastroenteritis Diseases 0.000 claims description 4
• 208000008665 Gastrointestinal Disease Diseases 0.000 claims description 4
• 208000001288 Gastroparesis Diseases 0.000 claims description 4
• 206010021518 Impaired gastric emptying Diseases 0.000 claims description 4
• 229940115931 Listeria monocytogenes Drugs 0.000 claims description 4
• 241000186779 Listeria monocytogenes Species 0.000 claims description 4
• 206010038683 Respiratory disease Diseases 0.000 claims description 4
• 206010040904 Skin odour abnormal Diseases 0.000 claims description 4
• 229940030998 Streptococcus agalactiae Drugs 0.000 claims description 4
• 241000193985 Streptococcus agalactiae Species 0.000 claims description 4
• 206010068760 Ulcers Diseases 0.000 claims description 4
• 201000006592 giardiasis Diseases 0.000 claims description 4
• 231100000404 nontoxic agent Toxicity 0.000 claims description 4
• 238000005507 spraying Methods 0.000 claims description 4
• 231100000397 ulcer Toxicity 0.000 claims description 4
• 206010014013 Ear infection Diseases 0.000 claims description 3
• 230000001665 lethal Effects 0.000 claims description 3
• 231100000518 lethal Toxicity 0.000 claims description 3
• 229910019093 NaOCl Inorganic materials 0.000 claims description 2
• 241000194017 Streptococcus Species 0.000 claims description 2
• 201000002146 gastrointestinal system disease Diseases 0.000 claims description 2
• 241000224436 Naegleria Species 0.000 claims 1
• 244000005700 microbiome Species 0.000 abstract description 9
• 230000001225 therapeutic Effects 0.000 abstract description 8
• 239000000463 material Substances 0.000 description 37
• 239000003981 vehicle Substances 0.000 description 16
• 230000001717 pathogenic Effects 0.000 description 15
• 241000282414 Homo sapiens Species 0.000 description 13
• 238000003860 storage Methods 0.000 description 13
• 230000034994 death Effects 0.000 description 12
• 231100000517 death Toxicity 0.000 description 12
• 229920001343 polytetrafluoroethylene Polymers 0.000 description 11
• 239000000243 solution Substances 0.000 description 11
• 210000001124 Body Fluids Anatomy 0.000 description 10
• 210000001508 Eye Anatomy 0.000 description 10
• 210000003491 Skin Anatomy 0.000 description 10
• 239000000969 carrier Substances 0.000 description 10
• 239000000499 gel Substances 0.000 description 10
• -1 hypochlorite ions Chemical class 0.000 description 10
• 239000007788 liquid Substances 0.000 description 10
• 235000002639 sodium chloride Nutrition 0.000 description 10
• 239000007921 spray Substances 0.000 description 10
• 210000000214 Mouth Anatomy 0.000 description 9
• 239000004810 polytetrafluoroethylene Substances 0.000 description 9
• 241000894007 species Species 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 200000000019 wound Diseases 0.000 description 9
• 229920002068 Fluorinated ethylene propylene Polymers 0.000 description 8
• 239000004812 Fluorinated ethylene propylene Substances 0.000 description 8
• 241000282412 Homo Species 0.000 description 8
• 239000004696 Poly ether ether ketone Substances 0.000 description 8
• 102000030002 Prion Proteins Human genes 0.000 description 8
• 108091000054 Prion Proteins Proteins 0.000 description 8
• 229920002530 poly[4-(4-benzoylphenoxy)phenol] polymer Polymers 0.000 description 8
• 208000003703 Viral Hemorrhagic Fevers Diseases 0.000 description 7
• 206010052428 Wound Diseases 0.000 description 7
• 239000003814 drug Substances 0.000 description 7
• 239000011521 glass Substances 0.000 description 7
• 244000052769 pathogens Species 0.000 description 7
• 230000002265 prevention Effects 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 6
• 241000224438 Naegleria fowleri Species 0.000 description 6
• 206010037660 Pyrexia Diseases 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000006011 modification reaction Methods 0.000 description 6
• 229920003023 plastic Polymers 0.000 description 6
• 239000004033 plastic Substances 0.000 description 6
• 230000000241 respiratory Effects 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 210000001519 tissues Anatomy 0.000 description 6
• 210000004400 Mucous Membrane Anatomy 0.000 description 5
• 206010035664 Pneumonia Diseases 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 230000002498 deadly Effects 0.000 description 5
• 239000003937 drug carrier Substances 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 239000006210 lotion Substances 0.000 description 5
• 235000019645 odor Nutrition 0.000 description 5
• 210000000056 organs Anatomy 0.000 description 5
• 239000005022 packaging material Substances 0.000 description 5
• 239000008194 pharmaceutical composition Substances 0.000 description 5
• 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 4
• 210000001331 Nose Anatomy 0.000 description 4
• 229920001774 Perfluoroether Polymers 0.000 description 4
• 210000004304 Subcutaneous Tissue Anatomy 0.000 description 4
• 230000001154 acute Effects 0.000 description 4
• 229910052782 aluminium Inorganic materials 0.000 description 4
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 4
• 229920002313 fluoropolymer Polymers 0.000 description 4
• 239000004811 fluoropolymer Substances 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 239000004700 high-density polyethylene Substances 0.000 description 4
• SCKXCAADGDQQCS-UHFFFAOYSA-N performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 239000002952 polymeric resin Substances 0.000 description 4
• 230000002829 reduced Effects 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 239000006188 syrup Substances 0.000 description 4
• 235000020357 syrup Nutrition 0.000 description 4
• 241000193468 Clostridium perfringens Species 0.000 description 3
• 210000002683 Foot Anatomy 0.000 description 3
• 206010017943 Gastrointestinal conditions Diseases 0.000 description 3
• 206010018987 Haemorrhage Diseases 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 206010022114 Injury Diseases 0.000 description 3
• 229940051866 Mouthwash Drugs 0.000 description 3
• 206010028885 Necrotising fasciitis Diseases 0.000 description 3
• 241000193996 Streptococcus pyogenes Species 0.000 description 3
• 229940034610 Toothpaste Drugs 0.000 description 3
• 241000223229 Trichophyton rubrum Species 0.000 description 3
• 206010047461 Viral infection Diseases 0.000 description 3
• 208000001756 Virus Disease Diseases 0.000 description 3
• 238000001266 bandaging Methods 0.000 description 3
• 239000005388 borosilicate glass Substances 0.000 description 3
• 230000002939 deleterious Effects 0.000 description 3
• 239000003889 eye drop Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 125000001153 fluoro group Chemical group F* 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 230000002458 infectious Effects 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 239000002324 mouth wash Substances 0.000 description 3
• 239000002077 nanosphere Substances 0.000 description 3
• 201000007970 necrotizing fasciitis Diseases 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 210000004215 spores Anatomy 0.000 description 3
• 229910001220 stainless steel Inorganic materials 0.000 description 3
• 239000010935 stainless steel Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 239000000606 toothpaste Substances 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 201000008827 tuberculosis Diseases 0.000 description 3
• 241000712461 unidentified influenza virus Species 0.000 description 3
• 229960005486 vaccines Drugs 0.000 description 3
• 230000017613 viral reproduction Effects 0.000 description 3
• 241000712891 Arenavirus Species 0.000 description 2
• 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 2
• 241000606124 Bacteroides fragilis Species 0.000 description 2
• 208000003508 Botulism Diseases 0.000 description 2
• 210000004556 Brain Anatomy 0.000 description 2
• 241000589562 Brucella Species 0.000 description 2
• 241000722910 Burkholderia mallei Species 0.000 description 2
• 241001136175 Burkholderia pseudomallei Species 0.000 description 2
• 229940095731 Candida albicans Drugs 0.000 description 2
• 241000222122 Candida albicans Species 0.000 description 2
• 229940038704 Clostridium perfringens Drugs 0.000 description 2
• 241000606678 Coxiella burnetii Species 0.000 description 2
• 229940026599 Cryptosporidium parvum Drugs 0.000 description 2
• 241000223936 Cryptosporidium parvum Species 0.000 description 2
• 208000008960 Diabetic Foot Diseases 0.000 description 2
• 206010014071 Ebola disease Diseases 0.000 description 2
• 201000011001 Ebola hemorrhagic fever Diseases 0.000 description 2
• 241000194033 Enterococcus Species 0.000 description 2
• 241000194032 Enterococcus faecalis Species 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• 241000711950 Filoviridae Species 0.000 description 2
• 241000710831 Flavivirus Species 0.000 description 2
• 208000006572 Human Influenza Diseases 0.000 description 2
• 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
• 210000000987 Immune System Anatomy 0.000 description 2
• 208000000932 Marburg Virus Disease Diseases 0.000 description 2
• 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 2
• 241000893980 Microsporum canis Species 0.000 description 2
• 241000224016 Plasmodium Species 0.000 description 2
• 241000223960 Plasmodium falciparum Species 0.000 description 2
• 241000223821 Plasmodium malariae Species 0.000 description 2
• 229940118768 Plasmodium malariae Drugs 0.000 description 2
• 241001505293 Plasmodium ovale Species 0.000 description 2
• 241000223810 Plasmodium vivax Species 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 206010057190 Respiratory tract infection Diseases 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 241000607142 Salmonella Species 0.000 description 2
• 241000607768 Shigella Species 0.000 description 2
• 206010040550 Shigella infection Diseases 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 241001505901 Streptococcus sp. 'group A' Species 0.000 description 2
• 231100000765 Toxin Toxicity 0.000 description 2
• 241000893966 Trichophyton verrucosum Species 0.000 description 2
• 206010045146 Tularaemia Diseases 0.000 description 2
• 241000607626 Vibrio cholerae Species 0.000 description 2
• 241000607265 Vibrio vulnificus Species 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000000843 anti-fungal Effects 0.000 description 2
• 230000002421 anti-septic Effects 0.000 description 2
• 230000000840 anti-viral Effects 0.000 description 2
• 230000000740 bleeding Effects 0.000 description 2
• 231100000319 bleeding Toxicity 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 201000003486 coccidioidomycosis Diseases 0.000 description 2
• 230000001010 compromised Effects 0.000 description 2
• 230000000875 corresponding Effects 0.000 description 2
• 238000005202 decontamination Methods 0.000 description 2
• 230000003588 decontaminative Effects 0.000 description 2
• 230000000249 desinfective Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 230000002500 effect on skin Effects 0.000 description 2
• 229920001971 elastomer Polymers 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 231100000533 low birth weight Toxicity 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 238000003801 milling Methods 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 230000001264 neutralization Effects 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 244000045947 parasites Species 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 239000000546 pharmaceutic aid Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 230000000750 progressive Effects 0.000 description 2
• 230000004043 responsiveness Effects 0.000 description 2
• 230000003330 sporicidal Effects 0.000 description 2
• 239000007940 sugar coated tablet Substances 0.000 description 2
• 201000004647 tinea pedis Diseases 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 108020003112 toxins Proteins 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• 241000589291 Acinetobacter Species 0.000 description 1
• 240000006547 Aframomum angustifolium Species 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 241000700587 Alphaherpesvirinae Species 0.000 description 1
• 241000710929 Alphavirus Species 0.000 description 1
• 241000224482 Apicomplexa Species 0.000 description 1
• 241000712892 Arenaviridae Species 0.000 description 1
• 241001221859 Arthroderma flavescens Species 0.000 description 1
• 241000033579 Arthroderma phaseoliforme Species 0.000 description 1
• 241001260018 Arthroderma uncinatum Species 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 206010064097 Avian influenza Diseases 0.000 description 1
• 241000193830 Bacillus <bacterium> Species 0.000 description 1
• 241000606125 Bacteroides Species 0.000 description 1
• 241000537222 Betabaculovirus Species 0.000 description 1
• 230000036912 Bioavailability Effects 0.000 description 1
• 210000004369 Blood Anatomy 0.000 description 1
• 210000004204 Blood Vessels Anatomy 0.000 description 1
• 206010005913 Body tinea Diseases 0.000 description 1
• 210000000988 Bone and Bones Anatomy 0.000 description 1
• 241000588807 Bordetella Species 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108010043024 Botulinum Toxins Proteins 0.000 description 1
• 208000001183 Brain Injury Diseases 0.000 description 1
• 206010006334 Breathing abnormality Diseases 0.000 description 1
• 206010006451 Bronchitis Diseases 0.000 description 1
• 241001148106 Brucella melitensis Species 0.000 description 1
• 206010006500 Brucellosis Diseases 0.000 description 1
• 241000195940 Bryophyta Species 0.000 description 1
• 229940074375 Burkholderia mallei Drugs 0.000 description 1
• 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
• 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 210000001736 Capillaries Anatomy 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 241000288673 Chiroptera Species 0.000 description 1
• 241000606161 Chlamydia Species 0.000 description 1
• 241001647378 Chlamydia psittaci Species 0.000 description 1
• CWFOCCVIPCEQCK-UHFFFAOYSA-N Chlorfenapyr Chemical compound BrC1=C(C(F)(F)F)N(COCC)C(C=2C=CC(Cl)=CC=2)=C1C#N CWFOCCVIPCEQCK-UHFFFAOYSA-N 0.000 description 1
• 206010008631 Cholera Diseases 0.000 description 1
• 241000193163 Clostridioides difficile Species 0.000 description 1
• 241000193403 Clostridium Species 0.000 description 1
• 241000016773 Collybia cookei Species 0.000 description 1
• 210000001520 Comb Anatomy 0.000 description 1
• 241001445332 Coxiella <snail> Species 0.000 description 1
• 229940118765 Coxiella burnetii Drugs 0.000 description 1
• 241000221204 Cryptococcus neoformans Species 0.000 description 1
• 208000001840 Dandruff Diseases 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• 229940057307 Dihydrate Calcium Sulfate Drugs 0.000 description 1
• 208000002173 Dizziness Diseases 0.000 description 1
• 206010014612 Encephalitis viral Diseases 0.000 description 1
• 241000588914 Enterobacter Species 0.000 description 1
• 229940032049 Enterococcus faecalis Drugs 0.000 description 1
• 241000194031 Enterococcus faecium Species 0.000 description 1
• 231100000655 Enterotoxin Toxicity 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 241001480035 Epidermophyton Species 0.000 description 1
• 241001480036 Epidermophyton floccosum Species 0.000 description 1
• 108050004280 Epsilon toxin Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 241000588722 Escherichia Species 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 229940012356 Eye Drops Drugs 0.000 description 1
• 206010016256 Fatigue Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 210000003754 Fetus Anatomy 0.000 description 1
• 241000710781 Flaviviridae Species 0.000 description 1
• 241000628997 Flos Species 0.000 description 1
• 241000589601 Francisella Species 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 241001556449 Garrha rubella Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 241000224466 Giardia Species 0.000 description 1
• 241000224467 Giardia intestinalis Species 0.000 description 1
• 229940085435 Giardia lamblia Drugs 0.000 description 1
• 229940074045 Glyceryl Distearate Drugs 0.000 description 1
• 241000606790 Haemophilus Species 0.000 description 1
• 206010061192 Haemorrhagic fever Diseases 0.000 description 1
• 206010019233 Headache Diseases 0.000 description 1
• 210000002216 Heart Anatomy 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 229940037467 Helicobacter pylori Drugs 0.000 description 1
• 241000590002 Helicobacter pylori Species 0.000 description 1
• 241000035314 Henipavirus Species 0.000 description 1
• 241000711557 Hepacivirus Species 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 241000700739 Hepadnaviridae Species 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 241000709715 Hepatovirus Species 0.000 description 1
• 241000709721 Hepatovirus A Species 0.000 description 1
• 241000700586 Herpesviridae Species 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
• 206010022000 Influenza Diseases 0.000 description 1
• 208000002979 Influenza in Birds Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 210000000936 Intestines Anatomy 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• 229940090046 Jet Injector Drugs 0.000 description 1
• 210000003734 Kidney Anatomy 0.000 description 1
• 241000222712 Kinetoplastida Species 0.000 description 1
• 241000588748 Klebsiella Species 0.000 description 1
• 241000588915 Klebsiella aerogenes Species 0.000 description 1
• 241000588749 Klebsiella oxytoca Species 0.000 description 1
• 206010023497 Kuru Diseases 0.000 description 1
• GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
• 206010023927 Lassa fever Diseases 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 210000000088 Lip Anatomy 0.000 description 1
• 241000186781 Listeria Species 0.000 description 1
• 210000004185 Liver Anatomy 0.000 description 1
• 210000004072 Lung Anatomy 0.000 description 1
• 241000555676 Malassezia Species 0.000 description 1
• 210000004379 Membranes Anatomy 0.000 description 1
• 206010027202 Meningitis bacterial Diseases 0.000 description 1
• 241000035435 Menopon gallinae Species 0.000 description 1
• RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
• 241000192041 Micrococcus Species 0.000 description 1
• 241001480037 Microsporum Species 0.000 description 1
• 241001480000 Microsporum audouinii Species 0.000 description 1
• 241001260008 Microsporum equinum Species 0.000 description 1
• 210000004080 Milk Anatomy 0.000 description 1
• 244000128833 Mimulus luteus Species 0.000 description 1
• 241000712045 Morbillivirus Species 0.000 description 1
• 210000003097 Mucus Anatomy 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 229940010383 Mycobacterium tuberculosis Drugs 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 210000000282 Nails Anatomy 0.000 description 1
• 241000893974 Nannizzia fulva Species 0.000 description 1
• 241000818707 Nannizzia incurvata Species 0.000 description 1
• 229940097496 Nasal Spray Drugs 0.000 description 1
• 241000588650 Neisseria meningitidis Species 0.000 description 1
• 240000007639 Nepenthes mirabilis Species 0.000 description 1
• 206010053643 Neurodegenerative disease Diseases 0.000 description 1
• 210000000440 Neutrophils Anatomy 0.000 description 1
• 208000010195 Onychomycosis Diseases 0.000 description 1
• 206010068319 Oropharyngeal pain Diseases 0.000 description 1
• 241000713112 Orthobunyavirus Species 0.000 description 1
• 241000700732 Orthohepadnavirus Species 0.000 description 1
• 241000712464 Orthomyxoviridae Species 0.000 description 1
• 241000150218 Orthonairovirus Species 0.000 description 1
• 241000283898 Ovis Species 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241000282579 Pan Species 0.000 description 1
• 210000000496 Pancreas Anatomy 0.000 description 1
• 241000711504 Paramyxoviridae Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241000150350 Peribunyaviridae Species 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 241000588769 Proteus <enterobacteria> Species 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 206010037151 Psittacosis Diseases 0.000 description 1
• 206010037688 Q fever Diseases 0.000 description 1
• 206010037844 Rash Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 206010038435 Renal failure Diseases 0.000 description 1
• 241000712907 Retroviridae Species 0.000 description 1
• 241000606701 Rickettsia Species 0.000 description 1
• 229940046939 Rickettsia prowazekii Drugs 0.000 description 1
• 241000606697 Rickettsia prowazekii Species 0.000 description 1
• 241000710801 Rubivirus Species 0.000 description 1
• 241000533331 Salmonella bongori Species 0.000 description 1
• 241001138501 Salmonella enterica Species 0.000 description 1
• 206010039447 Salmonellosis Diseases 0.000 description 1
• 241000607720 Serratia Species 0.000 description 1
• 241000607715 Serratia marcescens Species 0.000 description 1
• 241000607766 Shigella boydii Species 0.000 description 1
• 241000607764 Shigella dysenteriae Species 0.000 description 1
• 241000607762 Shigella flexneri Species 0.000 description 1
• 241000607760 Shigella sonnei Species 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 210000000952 Spleen Anatomy 0.000 description 1
• 206010041925 Staphylococcal infection Diseases 0.000 description 1
• 241000191940 Staphylococcus Species 0.000 description 1
• 241000191963 Staphylococcus epidermidis Species 0.000 description 1
• 241000192087 Staphylococcus hominis Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 210000002784 Stomach Anatomy 0.000 description 1
• 229940076156 Streptococcus pyogenes Drugs 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 210000004243 Sweat Anatomy 0.000 description 1
• 206010042682 Swelling face Diseases 0.000 description 1
• 210000001550 Testis Anatomy 0.000 description 1
• 208000002474 Tinea Diseases 0.000 description 1
• 241000710924 Togaviridae Species 0.000 description 1
• 206010044008 Tonsillitis Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 241000223238 Trichophyton Species 0.000 description 1
• 241000893963 Trichophyton concentricum Species 0.000 description 1
• 241000893962 Trichophyton equinum Species 0.000 description 1
• 241001045773 Trichophyton erinacei Species 0.000 description 1
• 241001459572 Trichophyton interdigitale Species 0.000 description 1
• 241001480046 Trichophyton schoenleinii Species 0.000 description 1
• 241000893982 Trichophyton simii Species 0.000 description 1
• 241000985906 Trichophyton soudanense Species 0.000 description 1
• 241001480048 Trichophyton tonsurans Species 0.000 description 1
• 241001244272 Trichophyton vanbreuseghemii Species 0.000 description 1
• 241001480050 Trichophyton violaceum Species 0.000 description 1
• 241001621834 Trichophyton yaoundei Species 0.000 description 1
• 206010061393 Typhus Diseases 0.000 description 1
• 210000003932 Urinary Bladder Anatomy 0.000 description 1
• 241001662569 Usteria Species 0.000 description 1
• 210000004291 Uterus Anatomy 0.000 description 1
• 241000700647 Variola virus Species 0.000 description 1
• 241000607598 Vibrio Species 0.000 description 1
• 229940118696 Vibrio cholerae Drugs 0.000 description 1
• 208000001877 Whooping Cough Diseases 0.000 description 1
• 208000003152 Yellow Fever Diseases 0.000 description 1
• 241000710772 Yellow fever virus Species 0.000 description 1
• 241000607734 Yersinia <bacteria> Species 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive Effects 0.000 description 1
• 230000001058 adult Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 230000000172 allergic Effects 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 238000004458 analytical method Methods 0.000 description 1
• 230000001355 anti-mycobacterial Effects 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000003926 antimycobacterial agent Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 201000009904 bacterial meningitis Diseases 0.000 description 1
• 230000035514 bioavailability Effects 0.000 description 1
• 230000003115 biocidal Effects 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 229940053031 botulinum toxin Drugs 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 201000006824 bubonic plague Diseases 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
• OSGAYBCDTDRGGQ-UHFFFAOYSA-N calcium;sulfuric acid Chemical compound [Ca+2].OS(O)(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-N 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 230000001413 cellular Effects 0.000 description 1
• 230000001684 chronic Effects 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000000882 contact lens solution Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000002537 cosmetic Substances 0.000 description 1
• 201000007336 cryptococcosis Diseases 0.000 description 1
• 210000004748 cultured cells Anatomy 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000001472 cytotoxic Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001627 detrimental Effects 0.000 description 1
• 230000001079 digestive Effects 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 229940079593 drugs Drugs 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 238000005868 electrolysis reaction Methods 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000002708 enhancing Effects 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 210000004904 fingernail beds Anatomy 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 201000003641 glanders Diseases 0.000 description 1
• PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 239000008266 hair spray Substances 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 230000001771 impaired Effects 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 230000002262 irrigation Effects 0.000 description 1
• 238000003973 irrigation Methods 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 230000002147 killing Effects 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 201000008197 laryngitis Diseases 0.000 description 1
• 230000000670 limiting Effects 0.000 description 1
• 239000007934 lip balm Substances 0.000 description 1
• 230000001926 lymphatic Effects 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 201000005505 measles Diseases 0.000 description 1
• 201000004015 melioidosis Diseases 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 238000000034 method Methods 0.000 description 1
• 229960003085 meticillin Drugs 0.000 description 1
• 230000000813 microbial Effects 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 235000011929 mousse Nutrition 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 230000001537 neural Effects 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 201000000901 ornithosis Diseases 0.000 description 1
• 239000000123 paper Substances 0.000 description 1
• 230000001575 pathological Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000001814 pectin Substances 0.000 description 1
• 235000010987 pectin Nutrition 0.000 description 1
• 229920001277 pectin Polymers 0.000 description 1
• 201000005702 pertussis Diseases 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000003285 pharmacodynamic Effects 0.000 description 1
• 230000036231 pharmacokinetics Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 201000007100 pharyngitis Diseases 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 108090000623 proteins and genes Proteins 0.000 description 1
• 230000004800 psychological effect Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 230000001850 reproductive Effects 0.000 description 1
• 201000005404 rubella Diseases 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 239000002453 shampoo Substances 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 238000003892 spreading Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 101710011036 stiI Proteins 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000009120 supportive therapy Methods 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000002459 sustained Effects 0.000 description 1
• 230000002522 swelling Effects 0.000 description 1
• 201000010874 syndrome Diseases 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 201000003875 tinea corporis Diseases 0.000 description 1
• 201000010618 tinea cruris Diseases 0.000 description 1
• 201000005882 tinea unguium Diseases 0.000 description 1
• 230000002485 urinary Effects 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 201000002498 viral encephalitis Diseases 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1

Classifications

• A—HUMAN NECESSITIES
• A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
• A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
• A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
• A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
• A61M11/08—Pocket atomisers of the injector type
• A—HUMAN NECESSITIES
• A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
• A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
• A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A—HUMAN NECESSITIES
• A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
• A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
• A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
• A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
• B—PERFORMING OPERATIONS; TRANSPORTING
• B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
• B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
• B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
• B05B11/0035—Pen-like sprayers
• A—HUMAN NECESSITIES
• A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
• A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
• A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
• A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
• A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
• A61L2/0088—Liquid substances
• A—HUMAN NECESSITIES
• A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
• A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
• A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
• A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
• A61L2/22—Phase substances, e.g. smokes, aerosols or sprayed or atomised substances
• B—PERFORMING OPERATIONS; TRANSPORTING
• B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
• B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
• B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
• B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
• B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
• B05B11/1001—Piston pumps

Abstract

This invention describes systems and methods for prophylactic and therapeutic treatment for exposure to pathogenic microorganisms and other conditions. Particularly, hyper-lethal microorganisms can be eradicated by the systems and methods of using the compositions described herein.

Description

FIELD OF INVENTION This invention relates to prophylactic and therapeutic treatment for exposure to pathogenic microorganisms and other conditions

All publications herein are incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference The following description includes information that may be useful in understanding the present invention It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art

Various conditions and disease conditions are caused by infection by a pathogen For example, body odor (e gr , foot odor) is the scent of bacteria growing on the body These bacteria proliferate in the presence of sweat and, a non-pleasant odor is released Halitosis is another condition caused by bacteria One cause of halitosis is through proteins trapped in the mouth that are processed by oral bacteria Over 600 types of bacteria are typically found in the mouth and a portion of these bacteria can produce high levels of foul odors

Additional conditions caused by pathogenic infection include gastrointestinal disorders such as ulcers (e g , caused by Helicobacter pylon (H pylori)), gastroenteritis (e g , caused by viruses, bacteria or their toxins, or parasites), giardiasis (e g , caused by the protozoan Giardia lambha), diarrhea, vomiting, and gastroparesis (e g , caused by viral infections)

Generally, treatment for conditions caused by pathogenic infections exists in the art However, adverse effects to humans may occur as therapeutics may have some degree of toxicity to humans Thus, there is a need in the art for additional therapeutic treatments that may be non-toxic or have a lower level of toxicity to humans, and that may be more conveniently manufactured, easily administered and/or better tolerated i In many instances, upon exposure to a pathogenic microorganism, the response time is crucial to lower the subject's chances of becoming infected and thereby causing a harmful effect on the subject. While many infections are treatable, there are those that can become life-threatening. It would be especially helpful to prevent, treat and/or reduce the chances of experiencing the pathogenic microorganism's harmful effect on the subject. Even with treatable infections, it is still helpful to prevent, treat and/or reduce the chances of experiencing the pathogenic microorganism's harmful effect for non life-threatening diseases caused by them. Pathogenic microorganisms include but are not limited bacteria, viruses, prions, fungus, archaea, protist, protozoa, and their spores and/or endospores, and it is beneficial to prevent, treat and/or reduce the likelihood of experiencing their harmful effect. For example, Plasmodium (e.g., Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae) can infect humans and cause malaria. Thus, there is a need in the art to prevent, treat and/or reduce the likelihood of experiencing the pathogenic microorganism's harmful effect. The Centers for Disease Control and Prevention {"CDC") lists three categories of bioterrorism agents and diseases. While these agents and diseases are under the category of bioterrorism, outbreaks and transmission of these diseases do not necessarily need to occur as a result of a terrorist event. Category A includes organisms that can be easily transmitted from person to person, result in high mortality rates and have the potential for major public health impact. Diseases or disease conditions caused by bacteria included in Category A are anthrax (Bacillus anthracis), botulism (Clostridium botulinum toxin), plague (Yersinia pestis), and tularemia (Francisella tularensis). Category A, as it pertains to viruses, includes smallpox (variola major) and viral hemorrhagic fevers. Category B includes organisms that result in moderate morbidity rates and low mortality rates. Category B, as it pertains to bacteria, includes brucellosis (Brucella species), epsilon toxin of Clostridium perfringens, food safety threats (e.g., Salmonella species, Escherichia coli, Shigella), glanders (Burkholderia mallei), melioidosis (Burkholderia pseudomallei), psittacosis (Chlamydia psittaci), Q Fever (Coxiella burnetii), Staphylococcal enterotoxin B, typhus fever (Rickettsia prowazekii), and water safety threats (e.g., Vibrio cholerae, Cryptosporidium parvum). Category B, as it pertains to viruses, includes viral encephalitis (alphaviruses). Category C includes emerging organisms that can be engineered for mass dissemination because of their potential for high morbidity and mortality rates and major health impact; for example, Nipah virus and hantavirus. Pneumonia, which can be caused by bacteria, is one of the most common acute respiratory infections and it is responsible for numerous deaths worldwide, especially in children and the elderly. Children with low birth weight or compromised immune systems are more susceptible to the disease. The disease progresses rapidly if left untreated and it is spread via contact with the bodily fluids of infected individuals, especially via airborne inhalation of infected droplets containing the bacteria.

Necrotizing Fasciitis, commonly known as "flesh-eating disease" or "flesh- eating bacteria," is an infection of the deeper layers of skin and subcutaneous tissues, easily spreading across the fascial plane within the subcutaneous tissue. Many types of bacteria can cause necrotizing fasciitis (e.g., Group A streptococcus, Vibrio vulnificus, Clostridium perfringens, Bacteroides fragilis), of which Group A streptococcus (also known as Streptococcus pyogenes) is the most common cause. The infection begins locally, at a site of trauma, which may be severe (such as the result of surgery), minor, or even non-apparent. The affected skin is classically, at first, very painful without any grossly visible change. With progression of the disease, tissue becomes swollen, often within hours. Diarrhea and vomiting are common symptoms as well. Inflammation does not show signs right away if the bacteria are deep within the tissue. If they are not deep, signs of inflammation such as redness and swollen or hot skin show very quickly. Skin color may progress to violet and blisters may form, with subsequent necrosis of the subcutaneous tissues. Patients with necrotizing fasciitis typically have a fever and appear very ill. Mortality rates have been noted as high as 73%.

Tuberculosis (1TB") is a common and often deadly infectious disease caused by mycobacteria, mainly Mycobacterium tuberculosis. Although TB has been largely eradicated in many parts of the world through the use of vaccines, it is still a deadly killer in some regions. Moreover, some strains of TB are antibiotic resistant. TB is highly contagious, and only a small amount of the bacteria is needed to infect another person. Viral hemorrhagic fevers (VHFs), which refer to a group of illnesses that are caused by several distinct families of viruses, have severe multisystem syndrome effects. Typically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage and many of the viruses can cause severe, life-threatening disease. VHFs are caused by viruses of four distinct families: arenaviruses, filoviruses, bunyaviruses, and flaviviruses. With a few exceptions, there is no cure or established drug treatment for VHFs.

Viruses causing hemorrhagic fever (e.g., Ebola, Marburg, Lassa and Crimean-Congo hemorrhagic fever viruses) can be transmitted directly, through close contact with infected people or their body fluids, or indirectly, through contact with objects contaminated with infected body fluids (e.g., contaminated syringes and needles). Signs and symptoms of VHF include, marked fever, fatigue, dizziness, muscle aches, loss of strength, and exhaustion and in severe cases, bleeding under the skin, in internal organs, or from body orifices such as the mouth, eyes, or ears. Patients receive supportive therapy, but generally speaking, there is no other treatment or established cure for VHFs.

Ebola Hemorrhagic Fever is incredibly deadly, with a 90% fatality rate. It is transmitted via blood and bodily fluids from person to person. Ebola causes microscopic holes in capillary walls, leading to internal bleeding that contributes to the cause of death. It is mainly limited to areas in Africa, but little is known about the disease. Lassa Fever is an acute viral infection that occurs in some regions in Africa and causes approximately 5,000 deaths per year. While the disease is spread mainly via contact with rodent excrement, it, however, can also be spread via human contact with infected bodily fluids. The disease causes fever, sore throat, tremors, vomiting, diarrhea, and facial swelling. Marburg Hemorrhagic Fever is related to Ebola and originated in Africa. It is found in fruit bats, humans, and primates. The disease is also spread via exposure to bodily fluids. The symptoms include fever, rash, headache, jaundice, and delirium. It can also cause renal failure. With the exception of yellow fever and Argentine hemorrhagic fever, for which vaccines have been developed, no vaccines exist that can protect against these diseases. Therefore, prevention efforts must concentrate on avoiding contact with host species. Viruses that cause VHFs are only examples of potential viruses in which the prevention, treatment, and/or reduction in the chance of experiencing the virus' harmful effect is desired.

Another virus wherein prevention, treatment, or reduction in the chance of experiencing the virus' harmful effect would be beneficial is the human immunodeficiency virus ("HIV"), which leads to acquired immunodeficiency syndrome ("AIDS"). HIV/AIDS is one of the deadliest diseases known to man, as it has no known cure. HIV is transmitted through direct contact of a person's mucous membrane or bloodstream with infected bodily fluids. AIDS is considered a pandemic worldwide, as it kills approximately 2.1 million people per year. Although the disease is prevalent all over the world, the majority of deaths occur in Sub- Saharan Africa.

Severe Acute Respiratory Syndrome ("SARS") caused by a coronavirus known as the SARS-associated coronavirus ("SARS-CoV") is yet another virus. SARS is a respiratory disease that is fairly deadly in the elderly (50% mortality in those aged 65 and older). It caused a global alert in 2003 because the disease is easily spread from person to person via casual contact or direct contact with the bodily fluids of an infected individual.

Pneumonia, which can be caused by viruses, is one of the most common acute respiratory infections and it is responsible for numerous deaths worldwide, especially in children and the elderly. Children with low birth weight or compromised immune systems are more susceptible to the disease. The disease progresses rapidly if left untreated and it is spread via contact with the bodily fluids of infected individuals, especially via airborne inhalation of infected droplets containing the viruses. Pneumonia can also develop from exposure to the influenza virus. Influenza causes numerous deaths each year, and is responsible for 10,000-

40,000 deaths in the United States alone. The avian influenza strain (H5N1) is of great concern to scientists because of the possibility of mutation to become transmissible from human to human contact. Since the virus does not commonly infect humans, if the mutation does occur, it could be quite deadly and spread rapidly, causing a pandemic. The mortality rate for people infected with the disease is over 50%.

Additionally, prion diseases or transmissible spongiform encephalopathies (TSEs) are a family of rare progressive neurodegenerative disorders that affect both humans and animals. They are distinguished by long incubation periods, characteristic spongiform changes associated with neuronal loss, and a failure to induce inflammatory response. The causative agent of TSEs is believed to be a prion. A prion is an abnormal, transmissible agent that is able to induce abnormal folding of normal cellular prion proteins in the brain, leading to brain damage and the characteristics signs and symptoms of the disease. Prion diseases are usually rapidly progressive and always fatal.

Thus, there is a need in the art to prevent, treat and/or reduce the likelihood of experiencing the pathogenic microorganism's harmful effect.

Additionally, an outbreak of diseases caused by these pathogenic microorganisms may also incite fear and panic, which may compel healthcare providers to abandon those infected for fear of becoming inadvertently exposed and/or infected. For example, during an outbreak of the Ebola virus in Kinshasa, Uganda in 2000, many healthcare individuals refused to report to the hospital and demanded that the hospital be closed. Accordingly, having an agent that reduces pathogenic microorganism exposure burden to areas of the body that are not always protected or treated (e.g., mucous membrane exposure to eyes, nose and mouth), can prevent or reduce fear and panic. A reduction or the prevention of fear and panic associated with an outbreak will be beneficial and it would enable those in need of treatment to receive the necessary health care.

In cases of exposure, a person needs a product that works effectively and is safe to use anywhere by individuals such as consumers, patients, physicians, heath care workers, paramedics, first responders, military personnel and emergency workers.

Consequently, there is also a need in the art for a storage and delivery system to enable the use of such product anywhere. Selection of a storage system for a particular agent may be based on a variety of factors, such as the durability, cost, ease of manufacturing, or functionality of the storage system. However, the chemical properties of the agent and the relationship of those properties to the storage system must also be considered. So, too, must one consider the setting in which the storage system will be utilized. There are agents that might become altered, seep out of, interact with or otherwise be affected by the storage system material in such a manner that the agents lose their medicinal efficacy or the like. Thus, particularly in connection with pharmaceutical and medicinal agents, care must be exercised in selecting an appropriate storage system and materials to construct the same. Regarding the setting in which a storage system may be used, it might not be desirable to use, for example, a storage system constructed of a material that is easily breakable when the system is to be carried by an emergency worker in the field. There, the performance of even routine tasks may compromise the integrity of the storage system. It might become inoperative or shatter and spill its contents. Storage and delivery systems currently available in the art that enable individuals to conveniently transport small quantities of pharmaceuticals, medicants and other agents are frequently constructed from plastic, rubber and/or similar materials. However, as described above, many agents cannot be stored in such containers without losing efficacy or experiencing other undesirable effects. Moreover, the environment in which such storage and delivery systems may be used necessitates, in some cases, the use of a system that can withstand the exertion of anything from minor jostling to severe blunt force.

There is therefore a need in the art for a storage and delivery system that overcomes the aforementioned challenges to dispense the product to prevent, treat, and/or reduce the chance of experiencing the pathogenic microorganism's harmful effect.

Embodiments of the invention provide for a system to prevent, treat, and/or reduce the chance of experiencing a harmful effect from an actual or perceived exposure to a pathogenic microorganism in a mammal in need thereof, comprising an agent to prevent, treat and/or reduce the chance of experiencing the harmful effect; and a vehicle to dispense the agent to the mammal to prevent, treat and/or reduce the chance experiencing the harmful effect. In various embodiments, the agent may comprise oxychlorine compounds. In a particular embodiment, the agent may comprise about 99.99% oxidized water, sodium hypochlorite (NaOCl), hypochlorous acid (HOCI) and sodium chloride (NaCI). In various embodiments, the pathogenic microorganism may be selected from the group consisting of fungus, archaea, protest, protozoa, bacterium, bacterial spore, bacterial endospore, virus, viral vector, prion and combinations thereof.

In other embodiments, the pathogenic microorganism may be a hyper-lethal pathogenic microorganism. In certain embodiments, the hyper-lethal pathogenic microorganism may be selected from the group consisting of Naegleria fowleri, Coccidioides immitis, Bacillus anthracis, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitides, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus agalactiae, Pseudomonas aeruginosa, Yersinia pestis, Clostridium botulinum, Francisella tularensis, variola major, Nipah virus, Hanta virus, Pichinde virus, Crimean-Congo hemorrhagic fever virus, Ebola virus, Marburg virus, Lassa virus, Junfn virus, human immunodeficiency virus ("HIV"), SARS-associated coronavirus ("SARS-CoV"), prion that causes Creutzfeldt-Jakob Disease (CJD), prion that causes Variant Creutzfeldt-Jakob Disease (vCJD), prion that causes Gerstmann-Straussler-Scheinker Syndrome, prion that causes fatal familial insomnia, prion that causes bovine spongiform encephalopathy (BSE), prion that causes chronic wasting disease (CWD), prion that causes scrapie, prion that causes transmissible mink encephalopathy, prion that causes feline spongiform encephalopathy, and prion that causes ungulate spongiform encephalopathy. Embodiments of the present invention also provide for a method to prevent, treat, and/or reduce the chance of experiencing a harmful effect from an actual or perceived exposure to a pathogenic microorganism in a mammal in need thereof, comprising: providing an agent to prevent, treat and/or reduce the chance of experiencing the harmful effect; and administering the agent to the mammal to prevent, treat and/or reduce the chance of the experiencing the harmful effect. In certain embodiments, the method may further comprise providing the agent in a vehicle to dispense the agent.

In various embodiments, the agent may comprise oxychlorine compounds. In a particular embodiment, the agent may comprise about 99.99% oxidized water, sodium hypochlorite (NaOCI), hypochlorous acid (HOCI) and sodium chloride (NaCI). In various embodiments, the pathogenic microorganism may be selected from the group consisting of fungus, archaea, protest, protozoa, bacterium, bacterial spore, bacterial endospore, virus, viral vector, prion and combinations thereof. In other embodiments, the pathogenic microorganism may be a hyper-lethal pathogenic microorganism. In certain embodiments, the hyper-lethal pathogenic microorganism may be selected from the group consisting of Naegleria fowleri, Coccidioides immitis, Bacillus anthracis, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitides, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus agalactiae, Pseudomonas aeruginosa, Yersinia pestis, Clostridium botulinum, Francisella tularensis, variola major, Nipah virus, Hanta virus, Pichinde virus, Crimean-Congo hemorrhagic fever virus, Ebola virus, Marburg virus, Lassa virus, Junin virus, human immunodeficiency virus ("HlV"), SARS-associated coronavirus ("SARS-CoV"), prion that causes Creutzfeldt-Jakob Disease (CJD), prion that causes Variant Creutzfeldt-Jakob Disease (vCJD), prion that causes Gerstmann-Straussler-Scheinker Syndrome, prion that causes fatal familial insomnia, prion that causes bovine spongiform encephalopathy (BSE), prion that causes chronic wasting disease (CWD), prion that causes scrapie, prion that causes transmissible mink encephalopathy, prion that causes feline spongiform encephalopathy, and prion that causes ungulate spongiform encephalopathy.

In various embodiments, administering the agent may comprise administering via an aerosol, topical, ocular, nasal, oral, auricular, anal, vaginal, urethral, transmucosal, transdermal, enteral, or parental route. In a particular embodiment, administering the agent may comprise spraying the agent onto an affected surface of the mammal.

Embodiments of the present invention also provide for a method to prevent and/or reduce the chances of transmission of a pathogenic microorganism to a subject, comprising: providing an agent to prevent, treat and/or reduce a chance of experiencing a pathogenic microorganism's harmful effect; and applying the agent to a fomite to prevent or reduce the chances of transmission of the pathogenic microorganism to the subject.

In one embodiment, the agent may comprise oxychlorine compounds. In another embodiment, the agent may comprise oxidized water, sodium hypochlorite (NaOCI), hypochlorous acid (HOCI) and sodium chloride (NaCI).

In a certain embodiment, applying the agent may comprise spraying the agent onto the fomite. Embodiments of the present invention also provide for a method to treat a condition caused by an infection by a pathogenic microorganism in a mammal in need thereof, comprising: providing a non-toxic or substantially non-toxic agent capable treating the condition; and administering the agent to the mammal to treat the condition.

In one embodiment, the agent may comprise oxychlorine compounds. In a particular embodiment, the agent may comprise oxidized water, sodium hypochlorite (NaOCI), hypochlorous acid (HOCI) and sodium chloride (NaCI).

In various embodiments, the pathogenic microorganism may be selected from the group consisting of fungus, archaea, protest, protozoa, bacterium, bacterial spore, bacterial endospore, virus, viral vector, prion and combinations thereof. In various embodiments, the condition may be selected from the group consisting of ulcer, gastroenteritis, diarrhea, vomiting, gastroparesis, halitosis, body odor, foot odor, respiratory disorder, gastrointestinal disorder, giardiasis, and ear infection.

In certain embodiments, administering the non-toxic or substantially non-toxic agent may comprise administering via an aerosol, topical, ocular, nasal, oral, auricular, anal, vaginal, urethral, transmucosal, transdermal, enteral, or parental route.

Exemplary embodiments are illustrated in referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive. Figure 1 depicts a perspective view of a vial and dispenser assembly in accordance with an embodiment of the present invention.

Figure 2 depicts an exploded, perspective view of the vial and dispenser assembly shown in Figure 1 , in accordance with an embodiment of the present invention. Figure 3 depicts a cross-sectional view of the vial and dispenser assembly shown in Figure 1 , in accordance with an embodiment of the present invention.

io Figure 4 depicts a perspective view of the vial and dispenser assembly shown in Figure 1 in combination with a barrel and cap (the cap is in the open position), in accordance with an embodiment of the present invention.

Figure 5 depicts an exploded, perspective view of the vial and dispenser assembly with the barrel and cap shown in Figure 4, in accordance with an embodiment of the present invention.

Figure 6 depicts a cross-sectional view of the vial and dispenser assembly with the barrel and cap (the cap is in the closed position) shown in Figure 4, in accordance with an embodiment of the present invention. Figure 7 depicts a top perspective view of a barrel, in accordance with an embodiment of the present invention.

Figure 8 depicts a bottom perspective view of a cap, in accordance with an embodiment of the present invention.

All references cited herein are incorporated by reference in their entirety as though fully set forth. Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et a/. , Dictionary of Microbiology and Molecular Biology 3"* ed., J. Wiley & Sons (New York, NY 2001 ) and March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 5th ed., J. Wiley & Sons (New York, NY 2001) provide one skilled in the art with a general guide to many of the terms used in the present application.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

"Beneficial effects" may include, but are in no way limited to, lessening or alleviating the severity of a disease, a condition or a symptom thereof; preventing or lowering the chances of having the disease, the condition or the symptom thereof from worsening; curing the disease or the condition; and prolonging a subject's life or life expectancy.

I l "Conditions" and "disease conditions," as used herein may include, but are in no way limited to those caused by pathogenic microorganisms. Examples include, but are not limited to, halitosis, body odor, foot odor, respiratory disorders (e.g., sinusitis, tonsillitis, bronchitis, pharyngitis, laryngitis, pneumonia, and tuberculosis), gastrointestinal disorders (e.g., ulcers and other pathologies resulting from

Helicobacter pylori (H. pylori) infection, gastroenteritis [caused by viruses, bacteria or their toxins, or parasites], giardiasis [cause by the protozoan Giardia lamblia], diarrhea, vomiting, gastroparesis [caused by viral infections]), and ear infections. Additionally examples of conditions and disease conditions are described throughout the specification.

"Mammal" as used herein refers to any member of the class Mammalia, including, without limitation, humans and nonhuman primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be included within the scope of this term.

"Pathogenic microorganism" as used herein refers to a microorganism or infectious agent that causes a harmful effect on a mammal. These microorganism or infectious agent include, but are not limited to, bacteria, viruses, viral vectors, prions, fungi, archaea, protists [Cryptosporidium parvum), protozoas (e.g., Kinetoplastids, Apicomplexa, Plasmodium [e.g., Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae]) and their spores or endospores.

Examples of fungi include, but are not limited to, Candida albicans, Malassezia (also known as Pityrosporum, and causes dandruff), Microsporum (e.g., M. audouinii, M. canis, M. canis van distortum, M. cookei, M. equinum, M. ferrυgineum, M. fulvum, M. gallinae, M. gypseum, M. nan urn, M. persicofoή, Trichophyton (e.g., T. ajelloi, T. concentricum, T. equinum, T. flavescens, T, gloriae, T. megnini, T. mentagrophytes var. erinacei, T. mentagrophytes var. interdigitale, T. phaseoliforme, T. rubrum, T. rubrum downy strain, T. rubrum granular strain, T. schoenleinii, T. simii, T. soudanense, T, terrestre, T. tonsurans, T. vanbreuseghemii, T. verrucosum, T. violaceum, T. yaoundei) and Epidermophyton (e.g., E. floccosum, a cause of tinea corporis (ringworm), tinea cruris, tinea pedis (athlete's foot), and tinea unguium, (a fungal infection of the nail bed), Candida species (e.g., Candida albicans), Cryptococcus neoformans, Aspergillus, Naegleria fowleri (brain eating amoeba), and Coccidioides immitis (causing coccidioidomycosis, a.k.a., Valley Fever meningitis). "Pathology" of the condition or disease condition includes all phenomena that compromise the well-being of the patient.

"Bacteria" as used herein include to bacteria, bacterial spores, and bacterial endospores that cause a harmful effect on a mammal. Examples of bacteria include, but are not limited to, Acinetobacter (e.g., A. baumannii), Bacillus (e.g., B. anthracis), Bacteroides (e.g., B. fragilis), Bordetella (e.g., pertussis), Brucella (e.g., B. melitensis), Burkholdeήa (e.g., B. mallei, B. pseudomallei), Chlamydia (e.g., C. psittacf), Clostridium (e.g., C. difficile, C. botulinum, C. perfringens), Coxiella (e.g., C. burnetii), Enterobacter(e.g., E. aerogenes), Enterococcus (e.g., E. faecalis), Enterococcus (e.g., E. faecium), Escherichia (e.g., E. coli), Francisella (e.g., F. tuiarensis), Haemophilus (e.g., H. influenzae), Listeria (e.g., L monocytogenes), Klebsiella (e.g., K. oxytoca, K. pneumoniae), Micrococcus (e.g., M. luteus), Mycobacterium (e.g., M. tuberculosis), Neisseria (e.g., N. gonorrhoreae, N. meningitidis), Proteus (e.g., P. mirabilis), Pseudomonas (e.g., P aeruginosa), Rickettsia (e.g., R prowazekii), Salmonella (e.g., S. bongori, S. enterica), Serratia (e.g., S. marcescens), Shigella (e.g., S. boydii, S. dysenteriae, S. flexneri, S. sonnei), Staphylococcus (e.g., S. aureus [including Methicillin-resistant Staphylococcus aureus ("MRSA")], S. epidermidis, S. haemolyticus, S. hominis, S. saprophytics), Streptococcus (e.g., S. pneumoniae, S. pyogenes), Vibrio (e.g., V. cholerae, V. vulnificus), and Yersinia (e.g., Y. pestis). "Virus" as used herein includes viruses and viral vectors that cause a harmful effect on a mammal. Examples of viruses include, but are not limited to, Picomavirus (e.g., Hepatovirus genus, hepatitis A virus species), Hepadnaviridae family (e.g., Orthohepadnavirus genus [e.g., Hepatitis B virus species]), Flaviviridae family (e.g., Hepacivirus genus [e.g., Hepatitis C virus species], Flavivirus genus [e.g., Yellow fever virus species), cold virus, Orthomyxoviridae family (e.g., human influenza viruses, avian influenza viruses [e.g., H5N1]), Herpesviridae family (e.g., Alphaherpesvirinae Subfamily, Simplexvirus Genus [e.g., herpes simplex virus type 1 (HSV-1) species, herpes simplex virus type 2 (HSV-2) species]), variola major

I3 species, Henipavirus genus {e.g., Nipah virus species), Bunyaviridae family (e.g, hantavirus genus, Nairovirus genus [e.g., Crimean-Congo hemorrhagic fever virus]), Filoviridae family {e.g., Ebolavirus genus [e.g., Ebola virus species], Marburgvirus genus, [e.g., Marburg virus species]), Arenaviridae family (e.g., Arenavirus genus [e.g., Lassa virus species, Junin virus species (causing Argentine hemorrhagic fever)]), Retroviridae family (e.g., Lentivirus genus [e.g., human immunodeficiency virus ("HIV") species], Coronavirus genus (e.g., SARS-associated coronavirus ("SARS-CoV") species), viruses that cause pneumonia, Paramyxoviridae family (e.g., Morbillivirus species (causing measles)), Togaviridae family (e.g., Rubivirus genus [e.g. Rubella virus species (causing German measles)]), and Pichinde virus (e.g., strain CoAn4763).

"Harmful effect" as used herein includes, but is in no way limited to, any detrimental effect to a mammal's health. Examples of harmful effects include, but are not limited to, infection by a pathogenic microorganism (acute or chronic), a disease caused by the pathogenic microorganism, a disease condition caused by the pathogenic microorganism, becoming a carrier of the pathogenic microorganism (and thereby potentially imparting a harmful effect to another mammal), alteration of the microbial flora in or on a physiological structure of the mammal (e.g., organs such as heart, lungs, brain, eyes, stomach, spleen, bones, pancreas, kidneys, liver, intestines (small and large), skin, bladder, uterus and testicles; systems such as digestive, respiratory, nervous, circulatory, endocrine, lymphatic, reproductive, urinary, skeletal and muscular; and membranes such as mucus, basement and serous), pain, discomfort, swelling, inflammation, discomfort, psychological effects, fear, panic, and death.

"Hyper-lethal microorganisms" as used herein refers to pathogenic microorganisms that when actively infect a mammalian subject (e.g., human) results in the death of the mammalian subject in an unusually high rate. "Hyper-lethal microorganisms" include but are not limited to hyper-lethal bacteria, hyper-lethal viruses, hyper-lethal prions, as well the following microorganisms: Naegleria fowleri (brain eating amoeba) and Coccidioides immitis (causing coccidioidomycosis, a.k.a., Valley Fever meningitis). "Hyper-lethal bacteria" as used herein refer to bacteria, bacterial spores and bacterial endospores that when actively infect a mammalian subject (e.g., human) results in the death of the mammalian subject in an unusually high rate. "Hyper- lethal bacteria" include but are not limited to the following bacteria: Bacillus anthracis; Haemophilus influenzae, Usteria monocytogenes, Neisseria meningitides, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus agalactiae, and Pseudomonas aeruginosa (causing bacterial meningitis); Yersinia pestis (causing the Bubonic Plague); Clostridium botulinum (causing botulism); and Francisella tularensis (causing tularemia). "Hyper-lethal viruses" as used herein refer to viruses that when actively infect a mammalian subject (e.g., human) results in the death of the mammalian subject in an unusually high rate. "Hyper-lethal viruses" includes but are not limited to the following viruses: variola major, Nipah virus, Hanta virus, Pichinde virus, particularly, strain CoAn4763, Crimean-Congo hemorrhagic fever virus, Ebola virus, Marburg virus, Lassa virus, Junin virus, human immunodeficiency virus ("HIV"), and SARS- associated coronavirus ("SARS-CoV").

"Hyper-lethal prions" as used herein refers to prions that when actively infect a mammalian subject (e.g., human) results in the death of the mammalian subject in an unusually high rate. "Hyper-lethal prions" include but are not limited to prions that cause Creutzfeldt-Jakob Disease (CJD), Variant Creutzfeldt-Jakob Disease (vCJD), Gerstmann-Straussler-Scheinker Syndrome, fatal familial insomnia, Kuru, bovine spongiform encephalopathy (BSE), chronic wasting disease (CWD), scrapie, transmissible mink encephalopathy, feline spongiform encephalopathy, and ungulate spongiform encephalopathy. "Treatment" and "treating," as used herein refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder even if the treatment is ultimately unsuccessful. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

Various embodiments of the present invention describe the use of non-toxic antimicrobial, oxychlorine, hypochlorous acid or superoxidized water products to treat a condition.

One embodiment of the present invention provides for a method to treat a condition in a mammal in need thereof, comprising: providing a non-toxic antimicrobial agent; and administering the agent to the mammal to treat the condition. The condition treated by the method of the present invention is any condition that is caused by an infection by a pathogen. The pathogen may be any pathogen as noted above. One of skill in the art will readily appreciate that the lists of pathogens above are not exhaustive and conditions caused by other pathogens may be treated by the present invention. Furthermore, one of skill in the art will readily appreciate that the various species noted above are representative of their genus; thus, the various embodiments of the present invention can be readily used on other species within the genus. Similarly, the genera noted above are representative of their families; thus, the various embodiments of the present invention can be used on other genera within the families. Administering the agent may be through any route of administration as noted below.

One embodiment of the present invention provides for a system for the prevention, treatment, and/or reduction of the chance of experiencing a harmful effect from exposure to a pathogenic microorganism, comprising an agent to prevent, treat and/or reduce the chance of a subject experiencing the harmful effect from exposure to the pathogenic microorganism. The system may further comprise a vehicle to dispense the agent.

Pathogenic microorganisms for which harmful effects may be prevented and/or treated, and/or for which the chance of experiencing a harmful effect may be reduced by the present inventive system include any of pathogenic microorganisms discussed above. However, the aforementioned list is not an exhaustive list of pathogenic microorganisms that may be prevented, treated and/or for which the chance of experiencing a harmful effect may be reduced by the present invention, as will readily be appreciated by those of skill in the art. Furthermore, one of skill in the art will readily appreciate that the various species noted above are representative of their genus; thus, the various embodiments of the present invention can be used on other species within the genus. Similarly, the various genera noted above are representative of their families; thus, the various embodiments of the present invention can be used on other genera within the families. In an embodiment of the present invention, the agent used to prevent, treat, and/or reduce the chance of experiencing a harmful effect by the present inventive system contains a pharmaceutically active ingredient in a carrier. The agent can be in any state; for example, liquid, solid, semi-solid, gel, gaseous. In another embodiment, the agent is antimicrobial, antiviral, antimycobacterial, antifungal and/or sporicidal. In another embodiment, the agent is substantially non-irritating to the eyes, ears, mouth, nose, wounds, mucous membranes and/or non-mucous membranes of a mammalian subject; particularly of a human subject. In another embodiment, the agent is substantially alcohol-free. In another embodiment, the agent contains a solution of oxychlorine compounds. In another embodiment, the agent comprises hypochlorous acid (HOCI) and hypochlorite ions (OCI ). In another embodiment, the agent comprises oxidized water, sodium hypochlorite (NaOCI), hypochlorous acid (HOCI) and sodium chloride (NaCI). In another embodiment, the agent contains about 99.99% oxidized water, sodium hypochlorite (NaOCI), hypochlorous acid (HOCI) and sodium chloride (NaCI).

In another embodiment, the agent is Microcyn® OTC Wound Care (available from Oculus Innovative Sciences, Inc.). In another embodiment, the agent is among the products described in U.S. Patent No. 7,090,753, or U.S. Patent Application Publication Nos. 2005/0142157, 2005/0139808, 2005/0196462, 2006/0235350, 2006/0241546, 2006/0253060, 2006/0272954, 2007/0173460, 2007/0173755,

2007/0196357, or 2007/0196434, each of which is incorporated by reference herein in its entirety as if fully set forth.

In another embodiment, the agent is a Sterilox™ solution (available from PuriCore pic). In another embodiment, the agent is among the products described in U.S. Patent Nos. 5,427,667, 5,540,819, 5,628,888, 5,635,040, 5,783,052, 5,871 ,623, 5,985,110, 6,004,439, 6,843,895, 6,632,347, 7,276,255, 6,528,214, 6,296,744, 6,752,757, 7,303,660 and U.S. patent application publication Nos. 2004/0060815, 2006/0124453, 2006/0249375, 2006/0278585, 2007/0017820, 2007/0051640, 2007/0108064, 2008/0075832, 2008/0156674, 2008/0160612, 2008/0156674, and 2008/0075832, each of which is incorporated by reference herein in its entirety as if fully set forth.

The agents described above generally impart the therapeutic effect by the oxychlorine compounds' ability to deactivate the microorganism's essential enzymes

I7 and structures, rendering them non-viable. (See, e.g., Landa-Solis et al., Microcyn®: a novel super-oxidized water with neutral pH and disinfectant activity. J. H OSP INFECT. 2005;61(4):291-299; Tanaka et al., Antimicrobial activity of super-oxidized water. J HOSP INFECT. 1996;34(1):43-49; DaIIa Paola et al., Use ofDermacyn®, a new antiseptic for the local treatment of diabetic foot ulcers. J WOUND HEALING.

2005;2:201; Altamirano, A-, Reducing Bacterial Infectious Complications from Burn Wounds. A look at the use of Oculus Microcyn® to treat wounds in Mexico. WOUNDS. 2006, Supp:17-19; Gutierrez, A., Super-Oxidized Water Kills Bacteria; Demonstrates Potential for Healing, DERMATOLOGY TIMES. 26{6), June 2005; Nakae e. a/., Effectiveness of electrolyzed oxidized water irrigation in a burn-wound infection model. J. TRAUMA. 2000;49{3):511-514; Ie Due et al., A Cytotoxic Analysis of Antiseptic Medication on Skin Substitutes and Autograft. BRITISH JOURNAL OF DERMATOLOGY. March 2007; Davis etal., An In Vitro Comparison of the Antimicrobial Effects of Various Endodontic Medicaments on Enterococcus faecalis. JOURNAL OF ENDODONTICS. 33(5), May 2007; Zahumensky, E., Infections and diabetic foot syndrome in field practice. VNITR LEK. 2006;52:411-416; and Veverkova et al., Methicilin-resistent Staphylococcus aureus - problem in health care. J WOUND HEALING. 2005, 2:201-202.)

The agents can generally be produced by the electrolysis of water and salt, resulting in the following chemical reaction to generate the active agents:

NaCl + H2O = NaOCI + HOCI = Na+ + H+ + OCI"

Hypochlorous acid (HOCI) and hypochlorite ions (OCI") react with a wide range of biological molecules. Notably, hypochlorous acid (HOCI) is produced by neutrophils in the human body in its defense against microorganisms and thus, is a suitable agent to use in the prevention, treatment and/or reduction of the chance of experiencing a harmful effect by a pathogenic microorganism in accordance with various embodiments of the present invention. Additionally, it is a suitable agent to use in the treatment of a condition caused by a pathogenic microorganism infection. Furthermore, in one embodiment, the pH of the agent can be neutral because both acids and bases are present creating a buffered solution.

In another embodiment, the agent is a SteriFx® composition and/or solution (available from SteriFx®, Inc.); for example, FreshFx® Antimicrobial Solution, VetFx® Wound Care Spray, CleanseFx® Antimicrobial Skin Cleanser, DeconFx™ is Decontamination Solution, Fx HSD Disinfectant and the compositions and/or solutions contained in the Personal Decontamination Kits available from SteriFx®. In another embodiment, the agent is among the products described in U.S. Patent No. 6,375,976, which is incorporated by reference herein in its entirety as if fully set forth. In another embodiment, the agent is among the products described in U.S. Patent Publication Nos. 2004/0211935 and 2002/0182264, each of which is incorporated by reference herein in its entirety as if fully set forth.

In another embodiment, the agent is among the products described in U.S. Patent No. 7,374,645. In another embodiment, the agent is an organosilane compound. In another embodiment, the agent is among the products described in U.S. Patent Nos. 5,959,014, 6,632,805, 6,221 ,944, 5,954,869, 6,113,815, 6,120,587, 6,469,120, or 6,762,172, each of which is incorporated by reference herein in its entirety as if fully set forth. The agent according to the present invention can also contain any pharmaceutically acceptable carrier. "Pharmaceutically acceptable carrier" as used herein refers to a pharmaceutically acceptable material, composition, or vehicle that is involved in carrying or transporting a compound of interest from one tissue, organ, or portion of the body to another tissue, organ, or portion of the body. For example, the carrier may be a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, or a combination thereof. Each component of the carrier must be "pharmaceutically acceptable" in that it must be compatible with the other ingredients of the formulation. It must also be suitable for use in contact with any tissues or organs with which it may come in contact, meaning that it must not carry a risk of toxicity, irritation, allergic response, immunogenicity, or any other complication that excessively outweighs its therapeutic benefits.

The pharmaceutical compositions according to the invention can also be in the form of tablets, gel capsules, sugar-coated tablets, syrups, suspensions, solutions, emulsions, powders, granules, emulsions, microspheres or nanospheres or lipid vesicles or polymer vesicles allowing controlled release encapsulated for oral route of administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil, glycerin, saline, alcohols and water. Solid carriers include starch, lactose, calcium sulfate, dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulation, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation may be in the form of a solution, syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.

The pharmaceutical compositions according to the invention may be delivered in a therapeutically effective amount. The precise therapeutically effective amount is that amount of the composition that will yield the most effective results in terms of efficacy of treatment in a given subject. This amount will vary depending upon a variety of factors, including but not limited to the characteristics of the therapeutic compound (including activity, pharmacokinetics, pharmacodynamics, and bioavailability), the physiological condition of the subject {including age, sex, disease type and stage, general physical condition, responsiveness to a given dosage, and type of medication), the nature of the pharmaceutically acceptable carrier or carriers in the formulation, and the route of administration. One skilled in the clinical and pharmacological arts will be able to determine a therapeutically effective amount through routine experimentation, for instance, by monitoring a subject's response to administration of a compound and adjusting the dosage accordingly. For additional guidance, see Remington: The Science and Practice of Pharmacy (Gennaro ed. 20th edition, Williams & Wtlkins PA, USA) (2000).

Typical dosages of an effective amount of the agent can be as indicated to the skilled artisan by the in vitro responses or responses in animal models. Such dosages typically can be reduced by up to about one order of magnitude in concentration or amount without losing the relevant biological activity. Thus, the actual dosage can depend upon the judgment of the physician, the condition of the patient, and the effectiveness of the therapeutic method based, for example, on the in vitro responsiveness of the relevant primary cultured cells or histocultured tissue sample, or the responses observed in the appropriate animal models.

In various embodiments, the carrier is a pharmaceutically acceptable excipient. "Pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and desirable, and includes excipients that are acceptable for veterinary use as well as for human pharmaceutical use. Such excipients may be solid, liquid, semisolid, gel or, in the case of an aerosol composition, gaseous.

In various embodiments, the agent according to the present invention may be formulated for delivery via any route of administration. "Route of administration" may refer to any administration pathway known in the art, including but not limited to aerosol, topical, ocular, nasal, oral, auricular, anal, vaginal, urethral, transmucosal, transdermal, enteral, or parenteral. "Parenteral" refers to a route of administration that is generally associated with injection, including intraorbital, infusion, intraarterial, intracapsular, intracardiac, intradermal, intramuscular, intraperitoneal, intrapulmonary, intraspinal, intrasternal, intrathecal, intrauterine, intravenous, subarachnoid, subcapsular, subcutaneous, transmucosal, or transtracheal. Via the parenteral route (or any other route where it would be appropriate), the compositions may be in the form of solutions or suspensions for infusion or for injection, or as lyophilized powders. Via the topical route, the pharmaceutical compositions based on agents according to the invention may be formulated for treating the skin and mucous membranes and are in the form of ointments, creams, milks, salves, powders, impregnated pads, solutions, gels, sprays, lotions or suspensions. They can also be in the form of microspheres or nanospheres or lipid vesicles or polymer vesicles or polymer patches and hydrogels allowing controlled release. These topical-route compositions can be either in anhydrous form or in aqueous form depending on the clinical indication. Furthermore, administration may be via jet spray. Jet spray applicators are known in the art. For example, Medi-Jector VISION® (available from Antares Pharma) uses pressure to create a micro-thin stream of insulin that penetrates the skin in a fraction of a second and is dispersed into subcutaneous tissue; SteriJect; and PenJet, a small, needle-less, disposable jet injector that delivers a single dose of medication, powered by self-contained compressed inert gas. These jet spray applicators may be used for dermal crevices, dermal surfaces, and subdermal surfaces (but not necessarily subcutaneously into blood vessels). Via the aerosol route, the agent may be formulated, for example, for use in a nebulizer, which may be useful to treat a respiratory condition caused by airborne pathogenic microorganisms, and their spores and/or endospores that may bring about a harmful respiratory effect. Via the enteral route, the pharmaceutical compositions can be in the form of tablets, gel capsules, sugar-coated tablets, syrups, suspensions, solutions, powders, granules, emulsions, microspheres or nanospheres or lipid vesicles or polymer vesicles allowing controlled release. Via the ocular route, they may be in the form of eye drops. In various particular embodiments, the agent is formulated as a mouthwash or toothpaste, or onto dental floss. Accordingly, these may be useful for treating conditions caused by pathogenic infections in the oral cavity; for example, halitosis.

In further embodiments, the agent may be provided in a cosmetic product (e.g., liquid or cream foundation, liquid, cream, or gel blush, lip gloss, lip balm, lipstick, liquid, gel or cream eye liner, mascara, nail polish). In still further embodiments, the agent may be provided in a cream, paste, gel, lotion, sunblock lotion, suntan lotion, contact lens solution, eye drop, ear drop, shampoo, conditioner, hair product {e.g., gel, hairspray, mousse), mouthwash, or toothpaste. The system may be used to on mammalian subjects and fomites. The fomites can be any inanimate object that may be contaminated with the pathogenic microorganisms and serve in their transmission. Examples of fomites include but are not limited to utensils, dishes, cups, toothbrushes, combs, microscopes, books, doorknobs, keys, clothing, goggles, gloves, bedding, light switches, and faucets. The vehicle to dispense the agent may be any vehicle that is suitable for delivery of the agent to a subject who has been exposed to or suspected to have been exposed to the pathogenic microorganism. Selection of an appropriate vehicle may depend on the route of administration and/or the location to which the agent is administered. It may be particularly useful to enable the agents to be used directly (e.g., sprayed) onto a subject's face or other body surface and into a subject's eyes, ears, mouth, nose, and open wounds.

Thus, in one embodiment, wherein the agent is sprayed onto or into the subject, or a body part of the subject, the vehicle may be a spray bottle. In a particular embodiment, the vehicle is an inert container and dispenser as set forth in Example 1 below.

In other embodiments, the vehicle may be: bandaging materials (e.g., wherein the agent is applied onto the subject via a wound dressing; for example, a wound dressing may be soaked with the agent and then applied and/or wrapped around the subject or a body part of the subject, or a wound dressing may be presoaked with the agent for convenience and quick application of the bandaging materials); a nasal spray device (e.g., wherein the agent is applied into the subject's nasal passageway); a eye drop or eye wash bottle, {e.g., wherein the agent is administered into the subject eyes); a bottle (e.g., to refill other delivery vehicles, to allow the subject to use it as a mouth wash, to pour the agent onto the subject, etc.); a tube {e.g., to store a gel, paste or lotion form of the agent); and pre-moistened wipes (e.g., packaged towels or blankets that can be conveniently opened and used to wipe a surface of the body).

Another embodiment of present invention provides for a method of preventing, treating and/or reducing the chance of experiencing a harmful effect from exposure to a pathogenic microorganism in a subject in need thereof, comprising providing an agent to prevent, treat and/or reduce the chance of experiencing a harmful effect from the pathogenic microorganism, providing a vehicle to dispense the agent, and administering the agent to the subject. In an alternative embodiment, the agent is provided in the vehicle. In various embodiments, the agent is administered directly onto a subject's face or other body surface and/or into a subject's eyes, ears, mouth, nose, and/or open wounds. In various embodiments, administering the agent may comprise administering the agent to the subject after the subject has actually or potentially been exposed to the pathogenic microorganism, and/or administering the agent after the subject has been in close proximity to or in contact with subjects or bodily fluids of subjects that are known to be or are suspected of being infected with or hosts of the pathogenic microorganism.

In various embodiments, the agents used to prevent, treat and/or reduce the chance of experiencing a harmful effect from the pathogenic microorganism are as described above. Similarly, the vehicles used to dispense the agent are as described above. Furthermore, administration can be by any route of administration as described above.

In another embodiment, the present invention provides for a method of preventing and/or reducing the transmission of a pathogenic microorganism to a subject, comprising providing an agent to prevent and/or reduce the chance of experiencing a harmful effect from the pathogenic microorganism, providing a vehicle to dispense the agent, and applying the agent to a fomite so that the transmission of the pathogenic microorganism to a subject is prevented and/or reduced. Similar to the method discussed above, the agent can alternatively be provided in the vehicle. The fomites can be any inanimate object that may be contaminated with the pathogenic microorganism and serve in their transmission as discussed supra.

The present invention is also directed to a kit to prevent, treat and/or reduce the chance of experiencing a harmful effect from exposure to a pathogenic microorganism. The kits may also be useful for treating a condition caused by pathogenic infection. The kit is an assemblage of materials or components, including at least one of the agents to prevent, treat and/or reduce the chance of experiencing a harmful effect from an exposure to a pathogenic microorganism as described above. Thus, in some embodiments, the kit contains a composition including an agent, as described above.

The exact nature of the components configured in the inventive kit depends on its intended purpose. For example, some embodiments are configured for the purpose of treating a first responder at or near the site of a trauma or for treating an aid worker or military personnel in an unsanitary, or pathogenic microorganism- ridden environment. Some embodiments are configured for the purposes of treating oral conditions, respiratory conditions, or gastrointestinal conditions caused by pathogenic infection. In one embodiment, the kit is configured particularly for the purpose of treating mammalian subjects. Some embodiments are configured for the purposes of treating oral conditions, respiratory conditions, or gastrointestinal conditions caused by pathogenic infection, in another embodiment, the kit is configured particularly for the purpose of treating human subjects. In further embodiments, the kit is configured for veterinary applications, treating subjects such as, but not limited to, farm animals, domestic animals, and laboratory animals.

Instructions for use may be included in the kit. "Instructions for use" typically include a tangible expression describing the technique to be employed in using the components of the kit to effect a desired outcome, such as to prevent, treat and/or reduce the chance of experiencing a harmful effect from an exposure to a pathogenic microorganism; or to treat a condition caused by pathogenic infection, such as oral conditions, respiratory conditions, or gastrointestinal conditions. Optionally, the kit also contains other useful components, such as, diluents, buffers, pharmaceutically acceptable carriers, syringes, catheters, applicators, pipetting or measuring tools, bandaging materials, spray bottles, cleansing wipes or other useful paraphernalia as will be readily recognized by those of skill in the art.

The materials or components assembled in the kit can be provided to the practitioner stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures. The components are typically contained in suitable packaging material(s). As employed herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as inventive compositions and the like. The packaging material is constructed by well known methods, preferably to provide a sterile, contaminant-free environment. In one embodiment, the packaging materials employed in the kit are those customarily utilized in first aid kits. As used herein, the term "package" refers to a suitable solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding the individual kit components. Thus, for example, a package can be an inert container and dispenser or a bottle used to contain suitable quantities of the agent. The packaging material generally has an external label which indicates the contents and/or purpose of the kit and/or its components.

The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.

As illustrated in Figures 1-3, in one embodiment, the device includes a vial 101 with a dispenser assembly 102. An agent 103 may be stored in the vial 101 and delivered by operation of the dispenser assembly 102.

The vial 101 illustratively depicted in Figures 1-3 is generally cylindrical along its axis, with a closed base 104 and an open top 105. External screw threading 106 surrounds the open top 105, to enable the mechanical interaction of the vial 101 with corresponding internal screw threading 107 on the dispenser assembly 102. The mechanical interaction of the external screw threading 106 on the vial 101 with the internal screw threading 107 on the dispenser assembly 102 may create a substantially fluid-tight seal between these elements. A washer 108 may be included between the open top 105 and the dispenser assembly 102 to provide an additional (and in some cases less permeable) fluid seal. The washer may be constructed from any suitable material, as will be readily appreciated by those of skill in the art, such as, alone or in combination, an elastomeric material, rubber, silicone, plastic, polytetrafluoroethylene ("PTFE;" available under the trade name Teflon® from DuPont Corporation), the fluoropolymer PFA (e.g., perfluoroalkoxy polymer resin; also available under the trade name Teflon® from DuPont Corporation), the Dyneon™ TFM™ range of chemically-modified PTFE (available from 3M), aluminum, polyetheretherketone (PEEK), fluorinated ethylene propylene (FEP), fluoro-treated high-density polyethylene (HDPE), and any number of other materials that are substantially inert or non-reactive with regard to the agent 103. In alternate embodiments of the present invention, different mechanisms may be used to affix the dispenser assembly 102 to the vial 101; for example, but in no way limited to, a snap fitting, a pressure fitting, a heat seal, a chemical adhesive or any number of other mechanical or chemical mechanisms readily known to those of skill in the art.

In alternate embodiments of the present invention, the vial 101 may be selected from any of a variety of shapes, such as, alone or in combination, cylindrical, rectangular, spheroid or any other desirable geometric configuration. In alternate embodiments, the via) 101 may have a shape that remains consistent or changes in cross-section along its axis, such as circular, elliptical, square, rectangular, rhomboid, trapezoidal, triangular, pentagonal, hexagonal, octagonal, and so on. As noted above, as illustratively depicted in Figures 1-3, the vial 101 is generally cylindrical and thus retains a generally circular shape along the entirety of its axis.

The vial 101 may be constructed from any suitable material. The material may be selected based upon, among other things, the chemical properties of the agent 103 that is to be contained in the vial 101. Specifically, it may be desirable to select a material that does not have a deleterious impact on the chemical composition, medicinal efficacy, stability or other properties of the agent 103; particularly insofar as the agent 103 is to be stored in the vial 101 for any appreciable amount of time, as may be necessitated by the intended use of the present invention. By way of example, in some embodiments the vial 101 may be constructed from various types of plastic, metal, stainless steel, glass (e.g., borosilicate glass), PTFE, the fluoropolymer PFA (e.g., perfluoroalkoxy polymer resin), the Dyneon™ TFM™ range of chemically-modified PTFE, aluminum, polyetheretherketone (PEEK), fluorinated ethylene propylene (FEP), fluoro-treated high-density polyethylene (HDPE), and any number of other materials that are substantially inert or non-reactive with regard to the agent 103. As will be readily appreciated by those of skill in the art, a variety of different materials may be used to construct the vial 101 and may be desirable based on the selection of various agents 103, and such materials are all contemplated as being within the scope of the present invention and can be readily used in alternate embodiments thereof without undue experimentation.

The dispenser assembly 102 may be selected from any apparatus useful to dispense the agent 103 from the vial 101. Those of skill in the art will recognize numerous such apparatuses, which may include, but are no way limited to, pump sprayers, squeeze tops (e.g., those akin to the end of a conventional tube of toothpaste), aerosol sprayers, eye-droppers and applicator pads. As illustratively depicted in Figure 1 , in one embodiment of the present invention, the dispenser assembly 102 is a pump sprayer, and is configured with conventional components, including a spray head 102a, a plunger 102b, a spring 102c, a ball 102d and a hole 102e. The components may be constructed from any desirable materials, which, in some embodiments, are inert with respect to the agent 103. The ball 102d may be constructed from any desirable material, which, in one embodiment, is stainless steel. Because certain components of the dispenser assembly 102 only come into contact with the agent 103 upon actuation {i.e., when a user dispenses the agent 103 from the vial 101), such components may need not be constructed of materials that are inert with respect to the agent. In those embodiments of the invention where the dispenser assembly 102 is a pump sprayer, the components that do not come into contact with the agent 103 until actuation may include the spray head 102a, plunger 102b, spring 102c and/or ball 102d.

Certain components of the dispenser assembly 102 may remain in fluid communication with the agent 103, irrespective of device actuation (e.g., during such time as the agent 103 is stored in the vial 101). For instance, in those embodiments of the present invention when the dispenser assembly 102 is a pump sprayer (as depicted in Figures 1-3 and 5), an insert portion 109 thereof may extend axially from the portion of the pump sprayer that remains external to the vial 101, into the interior of the vial 101 where the agent 103 is contained. In certain embodiments of the present invention it may be desirable for the insert portion 109 to be constructed of a material that does not have a deleterious impact on the chemical composition, medicinal efficacy or other properties of the agent 103. Therefore, in particular embodiments of the present invention, the insert portion 109 may be constructed from various types of glass (e.g., borosilicate glass), PTFE, the fluoropolymer PFA (e.g., perfluoroalkoxy polymer resin), the Dyneon™ TFM ™ range of chemically- modified PTFE, aluminum, polyetheretherketone (PEEK), fluorinated ethylene propylene (FEP), fluoro-treated high-density polyethylene (HDPE), and any number of other materials that are substantially inert or non-reactive with regard to the agent 103. The insert portion 109 may be substantially rigid and configured to reach a region of the vial 101 near its closed base 104, such that most, if not substantially all of the agent 103 contained in the vial 101 may be dispensed through operation of the dispenser assembly 102. In various embodiments of the present invention, the radial dimensions of the insert portion 109 may vary along its length, or, alternatively, remain substantially constant. In the embodiment illustratively pictured in Figures 1- 3 and 5, the insert portion 109 includes exterior radii of different dimensions along its length, as well as interior radii of increasingly narrow dimension from the end of the insert portion 109 nearest the open top 105 of the vial 101 to its closed base 104. Among other things, such a configuration may serve to accommodate the various components of the dispenser assembly 102 and/or minimize the amount of materia! needed to manufacture the insert portion 109. In an embodiment, the insert portion 109 is a unitary item, rather than several segments that are manufactured separately and adhered or otherwise affixed to one another; although both alternatives are envisioned as being within the scope of the instant invention.

In another embodiment of the present invention, as depicted in Figures 4-7, the vial 101 and dispenser assembly 102 may be fitted within a barrel 110 and cap 111. The vial 101 may be stabilized within the barrel by a series of support elements 112 in mechanical contact with the closed base 104 on one end, and a series of flanges 113 that grasp the vial about its open top 105 beneath the external screw threading 106. The series of flanges 113 may be configured to separate in a radial direction from one another to allow the vial 101 to be inserted into the barrel 110. Once inserted, the flanges 113 may provide the aforementioned grasping force to retain the vial 101 within the barrel 110, such that it cannot be easily removed therefrom or slide out of the barrel 110 during normal operation. In an alternate embodiment, the flanges 113 exert substantially minimal force on said vial 101, but instead retain the vial 101 within the barrel 110 by virtue of having a circumference generally smaller than that of the outer surface of the vial 101 ; such that the vial 101 cannot slide through the flanges 113 without substantial force.

The flanges 113 may have locking elements 114 on their exterior surface configured to mechanically interact with receiving elements 115 on the interior surface of the cap 111 (Figure 8). The mechanical interaction of the locking elements 114 with the receiving elements 115 may keep the cap 111 and barrel 110 affixed to one another until such time as the cap 111 is intentionally removed from the barrel 110 by a user. As illustrated in Figure 6, when the cap 111 and barrel 110 are locked together, the dispenser assembly 102 is protected from inadvertent use. In another embodiment, the cap 111 may include a tab 116, configured to allow a user to easily remove the cap 111 from the barrel 110 by dislodging the locking elements 114 from the receiving elements 115. As illustrated in Figure 6, in one embodiment, the tab 116 includes a forward portion 117 affixed to one side of the cap 111, a rear portion 118 configured to receive a mechanical force from a user to separate the cap 111 from the barrel 110, and an intermediate portion 119 therebetween. The angle between the forward portion 117 and the axis of the cap 111 may be from about 0°to about 10°; the angle between the intermediate portion 119 and the axis of the cap 111 may be from about 45° to about 55°, and in one embodiment, about 50°; and the angle between the rear portion 118 and the axis of the cap 111 may be from about 0° to about 8°. The rear portion 118 may include a surface 120 configured to receive the finger of a user, the generally radial force (i.e., including, at most, a minimal longitudinal component) of which upon the surface 120 may dislodge the cap 111 from the barrel 110.

In an alternative embodiment, the vial and barrel exists as a unitary barrel, rather than separate components that are manufactured separately and affixed to one another. In one embodiment, the dispenser assembly 102 is fitted directly onto the unitary barrel. For instance, the unitary barrel may have an external screw threading surrounding the open top (not shown) similar to the external screw threading 106 that is on the vial 101 described above, to enable the mechanical interaction of the barrel with the corresponding internal screw threading 107 on the dispenser assembly 102. The mechanical interaction of the external screw threading on the unitary barrel with the internal screw threading 107 on the dispense assembly 102 may create a substantially fluid-tight seal between these elements. A washer 108 may be included between the open top and the dispenser assembly 102 to provide an additional (in some cases less permeable) fluid seal. The unitary barrel may be constructed from any suitable material. The material may be selected based upon, among other things, the chemical properties of the agent 103 that is to be contained in the unitary barrel. Specifically, it may be desirable to select a material that does not have a deleterious impact on the chemical composition, medicinal efficacy, stability or other properties of the agent 103; particularly insofar as the agent 103 is to be stored in the unitary barrel for any appreciable amount of time, as may be necessitated by the intended use of the present invention. By way of example, in some embodiments the unitary barrel may be constructed from various types of plastic, metal, stainless steel, glass (e.g., borosilicate glass), PTFE, the fluoropolymer PFA (e.g., perfluoroalkoxy polymer resin), the Dyneon™ TFM™ range of chemically-modified PTFE, aluminum, polyetheretherketone (PEEK), fluorinated ethylene propylene (FEP)1 fluoro-treatecl high-density polyethylene (HDPE), and any number of other materials that are substantially inert or non-reactive with regard to the agent 103. As will be readily appreciated by those of skill in the art, a variety of different materials may be used to construct the unitary barrel and may be desirable based on the selection of various agents 103, and such materials are all contemplated as being within the scope of the present invention and can be readily used in alternate embodiments thereof without undue experimentation.

Germ-Killing, Antimicrobial/Anti-Viral/Anti-Fungal Activity, and/or Sporicidal Activity on a Surface Area of a Human Subject

A device as described herein is provided, including a glass vial with a pump sprayer, wherein the elements of the pump sprayer that are in direct contact with the agent contained in the device irrespective of device actuation are made from an inert material with respect to the agent. The glass vial includes a volume of an agent containing about 99.99% oxidized water, sodium hypochlorite (NaOCt)1 hypochlorous acid (HOCI) and sodium chloride (NaCI). The glass vial and pump sprayer are fitted within a plastic barrel and cap assembly; the cap includes a tab with a surface configured to receive a user's finger.

A user exerts a generally radial force on the tab surface; thereby releasing the cap from the barrel. The user then sprays a quantity of the agent onto a wound, into his eyes, into his ears, into his mouth and/or onto any additional surfaces of his body after being contacted by a substance believed to contain pathogens. The agent prevents, treats and/or reduces the chance of an experiencing a harmful effect on the surfaces to which it is applied.

Various embodiments of the invention are described above in the Detailed Description. While these descriptions directly describe the above embodiments, it is understood that those skilled in the art may conceive modifications and/or variations to the specific embodiments shown and described herein. Any such modifications or variations that fall within the purview of this description are intended to be included therein as well. Unless specifically noted, it is the intention of the inventors that the words and phrases in the specification and claims be given the ordinary and accustomed meanings to those of ordinary skill in the applicable art(s).

The foregoing description of various embodiments of the invention known to the applicant at this time of filing the application has been presented and is intended for the purposes of illustration and description. The present description is not intended to be exhaustive nor limit the invention to the precise form disclosed and many modifications and variations are possible in the light of the above teachings. The embodiments described serve to explain the principles of the invention and its practical application and to enable others skilled in the art to utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed for carrying out the invention.

While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from this invention and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this invention. It will be understood by those within the art that, in general, terms used herein are generally intended as "open" terms (e.g., the term "including" should be interpreted as "including but not limited to," the term "having" should be interpreted as "having at least," the term "includes" should be interpreted as "includes but is not limited to," etc.).

Claims

WHAT IS CLAIMED IS:

1. A system to prevent, treat, and/or reduce the chance of experiencing a harmful effect from an actual or perceived exposure to a pathogenic microorganism in a mammal in need thereof, comprising: an agent to prevent, treat and/or reduce the chance of experiencing the harmful effect; and a vehicle to dispense the agent to the mammal to prevent, treat and/or reduce the chance experiencing the harmful effect.

2. The system of claim 1 , wherein the agent comprises oxychlorine compounds.

3. The system of claim 1 , wherein the agent comprises about 99.99% oxidized water, sodium hypochlorite (NaOCl)1 hypochlorous acid (HOCI) and sodium chloride (NaCI).

4. The system of claim 1 , wherein the pathogenic microorganism is selected from the group consisting of fungus, archaea, protest, protozoa, bacterium, bacterial spore, bacterial endospore, virus, viral vector, prion and combinations thereof.

5. The system of claim 1 , wherein the pathogenic microorganism is a hyper- lethal pathogenic microorganism.

6. The system of claim 5, wherein the hyper-lethal pathogenic microorganism is selected from the group consisting of Naegleήa fowleri, Coccidioides immitis, Bacillus anthracis, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitides, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus agalactiae, Pseudomonas aeruginosa, Yersinia pestis, Clostridium botulinum, Francisella tularensis, variola major, Nipah virus, Hanta virus, Pichinde virus, Crimean-Congo hemorrhagic fever virus, Ebola virus, Marburg virus, Lassa virus, Junin virus, human immunodeficiency virus ("HIV"), SARS-associated coronavirus ("SARS-CoV"), prion that causes Creutzfeldt-Jakob Disease (CJD), prion that causes Variant Creutzfeldt-Jakob Disease (vCJD), prion that causes Gerstmann-Straussler-Scheinker Syndrome, prion that causes fatal familial insomnia, prion that causes bovine spongiform encephalopathy (BSE), prion that causes chronic wasting disease (CWD), prion that causes scrapie, prion that causes transmissible mink encephalopathy, prion that causes feline spongiform encephalopathy, and prion that causes ungulate spongiform encephalopathy.

7. A method to prevent, treat, and/or reduce the chance of experiencing a harmful effect from an actual or perceived exposure to a pathogenic microorganism in a mammal in need thereof, comprising: providing an agent to prevent, treat and/or reduce the chance of experiencing the harmful effect; and administering the agent to the mammal to prevent, treat and/or reduce the chance of the experiencing the harmful effect.

8. The method of claim 5, wherein the method further comprises providing the agent in a vehicle to dispense the agent,

9. The method of claim 5, wherein the agent comprises oxychlorine compounds,

10. The method of claim 5, wherein the agent comprises about 99.99% oxidized water, sodium hypochlorite (NaOCI), hypochlorous acid (HOCI) and sodium chloride (NaCI).

11. The method of claim 7, wherein the pathogenic microorganism is selected from the group consisting of fungus, archaea, protest, protozoa, bacterium, bacterial spore, bacterial endospore, virus, viral vector, prion and combinations thereof.

12. The method of claim 7, wherein the pathogenic microorganism is a hyper- lethal pathogenic microorganism.

13. The method of claim 12, wherein the hyper-lethal pathogenic microorganism is selected from the group consisting of Naegleria fowlers, Coccidioides immitis, Bacillus anthracis, Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitides, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus agalactiaβ, Pseudomonas aeruginosa, Yersinia pestis, Clostridium botulinum, Francisella tularensis, variola major, Nipah virus, Hanta virus, Pichinde virus, Crimean-Congo hemorrhagic fever virus, Ebola virus, Marburg virus, Lassa virus, Junin virus, human immunodeficiency virus ("HIV)1 SARS-associated coronavirus ("SARS-CoV"), prion that causes CreutzfeldKJakob Disease (CJD), prion that causes Variant Creutzfeldt-Jakob Disease (vCJD), prion that causes Gerstmann-Straussler-Scheinker Syndrome, prion that causes fatal familial insomnia, prion that causes bovine spongiform encephalopathy (BSE), prion that causes chronic wasting disease (CWD), prion that causes scrapie, prion that causes transmissible mink encephalopathy, prion that causes feline spongiform encephalopathy, and prion that causes ungulate spongiform encephalopathy.

14. The method of claim 7, wherein administering the agent comprises administering via an aerosol, topical, ocular, nasal, oral, auricular, anal, vaginal, urethral, transmucosal, transdermal, enteral, or parental route.

15. The method of claim 7, wherein administering the agent comprises spraying the agent onto an affected surface of the mammal.

16. A method to prevent and/or reduce the chances of transmission of a pathogenic microorganism to a subject, comprising; providing an agent to prevent, treat and/or reduce a chance of experiencing a pathogenic microorganism's harmful effect; and applying the agent to a fomite to prevent or reduce the chances of transmission of the pathogenic microorganism to the subject,

17. The method of claim 16, the agent comprises oxychlorine compounds.

18. The method of claim 16, wherein the agent comprises oxidized water, sodium hypochlorite (NaOCI), hypochlorous acid (HOCI) and sodium chloride (NaCI).

19. The method of claim 16, wherein applying the agent comprises spraying the agent onto the fomite.

20. A method to treat a condition caused by an infection by a pathogenic microorganism in a mammal in need thereof, comprising; providing a non-toxic or substantially non-toxic agent capable treating the condition; and administering the agent to the mammal to treat the condition.

21. The method of claim 20, wherein the agent comprises oxychlorine compounds.

22. The method of claim 20, wherein the agent comprises oxidized water, sodium hypochlorite (NaOCI), hypochlorous acid (HOC!) and sodium chloride (NaCI).

23. The method of claim 20, wherein the pathogenic microorganism is selected from the group consisting of fungus, archaea, protest, protozoa, bacterium, bacterial spore, bacterial endospore, virus, viral vector, prion and combinations thereof.

24, The method of claim 20, wherein the condition is selected from the group consisting of ulcer, gastroenteritis, diarrhea, vomiting, gastroparesis, halitosis, body odor, foot odor, respiratory disorder, gastrointestinal disorder, giardiasis, and ear infection.

25. The method of claim 20, wherein administering the non-toxic or substantially non-toxic agent comprises administering via an aerosol, topical, ocular, nasal, oral, auricular, anal, vaginal, urethral, transmucosal, transdermal, enteral, or parental route.

PCT/US2009/055258 2008-08-27 2009-08-27 Use of non-toxic antimicrobial, oxychlorine, hypochlorous acid and superoxidized water products WO2010025305A1 (en)

Applications Claiming Priority (8)

Publications (1)

Family

ID=41721938

Family Applications (1)

Country Status (1)

Cited By (2)

* Cited by examiner, † Cited by third party

Citations (1)

* Cited by examiner, † Cited by third party

• 2009
• 2009-08-27 WO PCT/US2009/055258 patent/WO2010025305A1/en active Application Filing

Patent Citations (2)

* Cited by examiner, † Cited by third party

Cited By (2)

* Cited by examiner, † Cited by third party

Similar Documents

Legal Events